Objective: The present study aimed to investigate the modulation of membrane-bound intercellular adhesion molecule-1 (mICAM-1) and soluble ICAM-1 (sICAM-1) expression by tumor necrosis factor-alpha (TNFa) in human osteoarthritic (OA) osteoblasts.
Introduction
Osteoarthritis (OA) is a disease characterized by progressive degradation of articular cartilage accompanied by secondary inflammation of the synovial membranes and abnormal subchondral trabecular bone remodeling 1, 2 . Several lines of evidence indicate that patients with OA exhibit high bone turnover involving both bone formation and resorption. Increased bone resorption followed by elevated bone and osteophyte formation have also been observed in experimental models of OA 3, 4 . It is believed that alterations in osteoblast metabolism play an important role in osteoclast maturation and activation by producing excess bone-resorbing cytokines and other pro-inflammatory mediators 5 . Such factors include urokinase plasminogen activator (uPA), insulin growth factor-1 (IGF-1) and prostaglandin E2 (PGE 2 ) 6e8 . In early experimental dog model of OA, Pelletier et al. showed a significant loss of subchondral bone associated with the development of OA cartilage lesions and with an increased osteoclast population that stained strongly positive for cathepsin K and metalloproteinase-13 (MMP-13) 3 . The use of a cyclooxygenase-2 (COX-2) inhibitor, licofelone, or bone resorption inhibitors, calcitonin or alendronate, suppressed bone resorption and prevented the subsequent increment of bone formation mainly through the inhibition of osteoclast activities 4, 9 . Adhesion molecules, such as integrins, and the immunoglobulin (Ig) superfamily of intercellular and vascular adhesion molecules (ICAM-1 and VCAM-1) play major roles in cellecell and celleextracellular matrix interactions 10 . Of these, ICAM-1 binds to its counter receptor leukocyte function-asssociated-1 molecule (LFA-1 or CD11a/CD18) as well as Mac-1 (CR3 or CD11a/CD18) on neutrophils, T-cells and macrophages 10e12 , providing a mechanism for the selective recruitment of leukocytes in different pathologic situations 13 . Many cytokines, such as interferon-gamma (IFN-g), interleukin-1 beta (IL-1b) and tumor necrosis factor-alpha (TNFa), induce ICAM-1 expression on the surface of synoviocytes 14 , keratocytes 15 , and human airway epithelial cells 16 . A soluble form of ICAM-1 (sICAM-1) is also detected in the serum of normal individuals, and elevated levels are found during various pathological conditions, including inflammatory, immune and malignant diseases 17e19 . However, the role of sICAM-1 and its mode of production remain elusive. Controversy still surrounds the exact origin of sICAM-1. In some cell types, proteolytic cleavage from membrane-bound ICAM-1 (mICAM-1) has been proposed as a mechanism for the generation of sICAM-1, and its presence would therefore reflect membrane expression of the protein 20, 21 . On the other hand, some researchers have identified a specific mRNA coding for sICAM-1 in cells, suggesting that at least two modes of sICAM-1 production exist 22, 23 . In bone metabolism, ICAM-1 exerts important osteotropic effects by mediating cellecell adhesion of osteoblasts and osteoclast precursors, thereby facilitating osteoclast differentiation and bone resorption 24, 25 . Furthermore, it has been shown that osteoblasts adhere to opposing cells through ICAM-1, VCAM-1 and LFA-3, resulting in the activation of intracellular signals and leading to the production of bone-resorbing cytokines, such as TNFa, IL-1b and IL-6. Interestingly, ICAM-1 expression and sICAM-1 release from cells are increased by these cytokines, which are found to be major contributors to bone diseases 26e28 . Abnormal sICAM-1 levels in bone diseases have been reported solely in rheumatoid arthritis so far, but no direct role has been attributed in the pathogenesis of this disease. Our group has demonstrated the induction of intracellular signaling in pre-osteoclast cells after incubation with sI-CAM-1 (study in progress), indicating a possible active role for sICAM-1 in osteoclast-dependent diseases. Although widely reported in other cell types, less attention has been paid to the regulation of mICAM-1 expression and sICAM-1 production in osteoblasts 14e16 . Therefore, the aim of this study was to demonstrate the effect of the bone-resorbing cytokine TNFa on mICAM-1 and sICAM-1 expression in human osteoblasts isolated from OA patients. We also wanted to examine whether sI-CAM-1 is cleaved from the membrane of osteoblasts by a proteolytic cleavage mechanism. We believe that clarifying the modulation and production of mICAM-1 and sI-CAM-1 in the bone environment could lead to a better understanding of their respective roles in bone pathology.
Materials and methods

IN VITRO OSTEOBLAST CULTURE
Trabecular bone specimens were collected from patients suffering from advanced OA and undergoing primary total knee replacement (n ¼ 36). The diagnosis was established according to American College of Rheumatology criteria 29 . The experimental protocol was approved by the Research Ethics Board at Sacre-Coeur Hospital. Bone specimens were taken within 5 mm of the subchondral bone plate. Every specimen was harvested from the most damaged portion of the tibial plateau. Osteoblast cultures were prepared as already described 5 . Briefly, trabecular bone samples were cut into small pieces of 2 mm 3 prior to their sequential digestion in the presence of 1 mg/ml collagenase type I (SigmaeAldrich, Oakville, ON, Canada) in BGJb media (Invitrogen Life Technologies, Burlington, ON, Canada) without serum at 37 C for 30, 30, and 240 min. After being washed with the same media, the digested bone pieces were cultured in 25 cm First-passage trabecular osteoblasts were incubated in 0.5% FBS/HAMF12/DMEM for 48 h with increasing concentrations of TNFa (0e10 ng/ml). After incubation, the culture medium was collected, and sICAM-1 level was quantified with a specific commercial kit from R&D Systems (Minneapolis, MN, USA), according to the manufacturer's instructions. The sensitivity of the assays was 3 pg/ml. Each ELISA was performed in duplicate according to the manufacturer's specifications. Protein level in the cell lysates was measured by the bicinchoninic acid method 33 .
IMMUNOCYTOCHEMICAL STAINING Cellular surface ICAM-1 expression was analyzed by immunocytochemical staining 34 . Osteoblasts (5 Â 10 3 ) were transferred to eight-well culture chamber slides (Lab-Tek, Nalge Nunc International, Naperville, IL, USA), and incubated for 16 h without or with 1 ng/ml TNFa (R&D Systems). Afterwards, the cells were washed twice with phosphate buffered salin (PBS) and fixed for 15 min at room temperature with PBS containing 10% formaldehyde (Tissufix, Laboratoire Gilles Chaput Inc., Montreal, QC, Canada). After washing three times with PBS, the cells were incubated for 30 min in a DAKO antibody diluent buffer containing mouse monoclonal anti-ICAM-1 antibody (DAKO, Carpinteria, CA, USA). In our experiments, we have used different dilution of the anti-mICAM antibody 1:100, 1:500, 1:1000, and 1:10,000. The optimal dilution of the antibody obtained in our experiments was 1:1000. Then, cells were washed with 0.05% TweenePBS and incubated for 10 min with goat anti-mouse IgGehorseradish peroxidase (HRP) conjugate (DAKO Envision System). Color was developed with 3,3 0 -diaminobenizidine (DAKO Liquid DAB) containing hydrogen peroxide, and the slides were examined under a light microscope (Leitz Orthoplan, Wild Leitz, Ville St-Laurent, QC, Canada). The numbers of total and coloured osteoblasts were counted separately, at 400Â magnification, from three fields of each well. The results were expressed as the percentage of coloured osteoblasts 34 .
SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA was extracted from the treated or un-treated osteoblasts using TRIzol reagent (Invitrogen Life Technologies), according to the manufacturer's instructions. RT-PCR was performed in a Thermocycler (Waterman, Biometra GmbH, Gö ttingen, Germany) with 1 mg of total RNA. These assays were undertaken with enzymes and reagents of the SuperScript one-step RT-PCR kit manufactured by Invitrogen Life Technologies. Each RT-PCR consisted of cDNA synthesis for 30 min at 42 C and denaturation for 5 min at 95 C, followed by an amplification cycle consisting of a denaturation step of 45 s at 95 C and an annealing/elongation step of 60 s at 55 C. For the last cycle, the elongation step was prolonged to 10 min at 72 C. Primers for the detection of mICAM-1 and sICAM-1 were based on those described previously by Wakatsuki et al. 23 . The sequences of the forward primer used to detect mICAM-1 and sICAM-1 were: 5 0 -CAA GGG GAG GTC ACC CGC GAG GTG-3 0 and 5 0 -CAA GGG AGG TCA CCC GCG AGC C-3 0 . Both primers were combined with a common reverse primer having the following sequence: 5 0 -TGC AGT GCC CAT TAT GAC TG-3 0 . The sequences for GADPH, which served as a positive control, were 5 0 -CCACCCATGGCAAATCCATGGCA-3 0 (forward) and 5
0 -TCTAGACGGCAGGTCAQGGTCCAQCC-3 0 (reverse) (BioCorp Inc., Montreal, QC, Canada).
RT-PCR products were separated on 2% agarose gel and stained with ethidium bromide solution (10 ng/ml). Semi-quantitative measurements were made by taking density readings of each band in a digital imaging system (G-image 2000, Canberra Packard Canada, Mississauga, ON, Canada). cDNA relative units for ICAM-1 were normalized to that of glyceraldehyde-6-phosphate dehydrogenase (GAPDH). The data were expressed as percentages of the non-treated control value 35 .
WESTERN BLOTTING Briefly, 20 mg of cellular protein extract were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions and transferred onto nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membranes were immersed for 3 h in a blocking solution consisting of TTBS (Tris 20 mM, pH 7.4, NaCl 137 mM, 0.1% Tween 20) and 5% skim milk, and washed twice with TTBS for 15 min. They were then incubated overnight in TTBS containing 0.25% skim milk, polyclonal rabbit anti-phospho-p38, anti-phospho-p44/42, anti-phospho-p54/ 46 mitogen-activated protein kinase (MAPK), anti-phospho-IkappaBalpha (IkBa) (1:1000, Cell Signaling Technology, Beverly, MA, USA), or anti-MMP-9 (1:1000, Calbiochem, San Diego, CA, USA). The membranes were washed three times with TTBS, and incubated for 1 h at 22 C with the second antibody anti-rabbit IgGeHRP (1:1000, Cell Signaling Technology), then washed again. Immunoreactive proteins were visualized with LumiGLO Chemiluminesent substrate (Cell Signaling Technology). The membranes were prepared for autoradiography and exposed to Kodak X-Omat film (Eastman Kodak Ltd., Rochester, NY, USA).
PROTEIN KINASES, NUCLEAR FACTOR-KAPPAB (NF-kB), AND MMP-9 INHIBITION
Osteoblasts were pre-incubated for 60 min with actinomycin D (ActD) (RNA polymerase II inhibitor), MAPK inhibitors (PD98059 and SB202190), NF-kB inhibitor (PDTC), or MMP-9 inhibitor I (Calbiochem) before the addition of 10 ng/ml TNFa for 24 h at 37 C. After incubation, mICAM-1 and sICAM-1 expressions were measured by immunocytochemical staining and ELISA as described above.
PLASMIDS AND TRANSIENT TRANSFECTIONS
The expression vectors for wild type (WT) pCMV-Flagp38 and dominant negative (DN) pCMV-Flag-p38 MAPK were kind gifts from Dr R.J. Davis (University of Massachusetts). The expression vector for IkappaB kinase alpha (IKKa) was generously donated by Dr M. Karin (University of California, San Diego, La Jolla, CA). Briefly, human MG-63 osteoblast-like line cells (ATCC, Rockville, MD, USA) (around 50% confluence) were transiently transfected with vectors of WT or DN p38 MAPK, or IKKa followed by stimulation with TNFa (10 ng/ml) in 12-well cluster plates using lipofectamine 2000Ô reagents (Invitrogen Life Technologies) according to the manufacturer's protocol. Twenty-four hours after transfection, the culture medium was collected and mICAM-1 expression levels were quantified by ELISA as described by Yang et al. with some modifications 36 . Briefly, the cells were washed twice with PBS and fixed at room temperature with 1% (w/v) paraformaldehyde/glutaraldehyde for 30 min. After washing with PBS, they were blocked with PBS containing 5% (w/v) bovine serum albumin and 0.05% (v/v) Tween 20 for 15 min before being incubated with monoclonal anti-ICAM-1 antibody (1:100) for 1 h and then with HRP-labeled anti-mouse antibody (1:1000) for 30 min. After each incubation, the cells were washed twice with PBS. Tetramethylbenzidine substrate (SigmaeAldrich) was then applied to them for 30 min, after which 1 M H 2 SO 4 acid was added to stop the reaction. Absorbance was measured at 450 nm.
STATISTICAL ANALYSIS
The results are expressed as means AE S.E.M.. All assays were performed in duplicate. Statistical significance was assessed by Student's t test, and P < 0.05 was considered significant.
Results
We first examined the presence of TNFa levels in osteoblast cultures to be certain that endogenous production would not influence ICAM-1 expression. TNFa could not be detected in the cell culture supernatant, even with a high-sensitivity ELISA kit (data not shown). However, the addition of increasing concentrations of TNFa to osteoblasts significantly enhanced mICAM-1 and sICAM-1 production [ Fig. 1(A and B) ]. These results were confirmed at the mRNA level in OA osteoblasts where, again, dosedependent increases of mICAM-1 and sICAM-1 were observed after TNFa stimulation, correlating with the protein expression pattern [ Fig. 1(C) ].
Immunostaining of osteoblasts with ICAM-1 antibody revealed that this protein was expressed at basal levels in unstimulated cells with a mean AE S.E.M. of 29 AE 6% (n ¼ 3 experiments) [ Fig. 2(A) ]. In the presence of 1 ng/ml TNFa (16 h of incubation), the percentage of positively-stained osteoblasts increased significantly with a mean AE S.E.M. of 87 AE 9% (n ¼ 3 experiments) [ Fig. 2(B) ]. Staining specificity was confirmed by substitution of the primary mICAM-1 antibody with an autologous preimmune serum [ Fig. 2(C) ]. Incubation of osteoblasts with 1 ng/ml TNFa for different incubation periods revealed that the effect on mICAM-1 surface expression was time-dependent as heightened surface expression was apparent as early as 4 h after exposure to TNFa, with a maximal effect at 16 h (results not shown).
Next, we demonstrated that TNFa increased mICAM-1 and sICAM-1 mRNA levels required de novo mRNA synthesis, by pre-incubating osteoblasts with ActD before adding 10 ng/ml TNFa (Fig. 3) . The expression of both mICAM-1
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Q Fig. 3(A and B) ] and sICAM-1 [ Fig. 3(C and D) ] at the mRNA and protein levels was completely blocked by the RNA synthesis inhibitor ActD. To gain insight into the signaling pathways activated by TNFa in human OA osteoblasts, we first examined the TNFa-induced phosphorylation patterns of MAPKs and NF-kB over increasing periods of time. Our data indicated that TNFa stimulated p38, p42/p44, and p54/46 MAPK as well as IkBa phosphorylation within 5 min (Fig. 4) . p38 MAPK remained in a phosphorylated state for w60 min of incubation, but p44/42, p54/46 MAPK and IkBa activation peaked at 15 min, and decreased thereafter at 60 min. No change in the total protein level of MAPKs was noted (data not shown).
To better define the TNFa signaling cascades involved in ICAM-1 synthesis, OA osteoblasts were pre-incubated with chemical inhibitors of p38 MAPK (SB202190), p44/42 (PD98059), and NF-kB (PDTC) before adding 10 ng/ml TNFa. mICAM-1 protein expression was reduced with SB202190 [ Fig. 5(A) ], PD98059 [ Fig. 5(B) ], and PDTC [ Fig. 5(C) ]. In contrast, TNFa-induced sICAM-1 release was not affected by any of the chemical inhibitors.
To clarify the role of p38 MAPK and IKKa in TNFa-mediating mICAM-1 production, we conducted transfection experiments with WT and DN vectors of p38 MAPK or IKKa after TNFa treatment. Overexpression of WT p38 MAPK or IKKa plasmids markedly increased basal mICAM-1 protein expression, and TNFa treatment further enhanced mICAM-1 expression compared to TNFa alone (Fig. 6) . However, overexpression of DN p38 MAPK abrogated this effect (data not shown).
Finally, to get a better understanding of MMP-mediating mICAM-1 cleavage, we used MMP-9 inhibitor I to evaluate other possible mechanisms involved in sICAM-1 production. We observed that the addition of MMP-9 inhibitor I (10 nM) significantly reduced 25% of TNFa-enhanced sICAM-1 release and did not change basal sICAM-1 production [ Fig. 7(A) ]. To confirm the ability of TNFa to induce MMP-9 synthesis, OA osteoblasts were treated with working concentrations of this cytokine (0.1e10 ng/ml), and MMP-9 was measured in the culture media. Western blotting analysis revealed that TNFa dose-dependently increased MMP-9 release by osteoblasts [ Fig. 7(B) ].
Discussion
ICAM-1 has previously been reported to be involved in osteoclast differentiation and bone resorption. In a co-culture system of mouse spleen cells and osteoblasts or stromal cells, cellular interaction through ICAM-1 could be blocked by anti-CD54 monoclonal antibodies, which resulted in decreased osteoclast formation in vitro 24, 25 . Further, a previous study by our group showed that ICAM-1 The gel is representative of three independent experiments. mRNA levels (arbitrary units) were then quantified by densitometry. mICAM-1 and sICAM-1 levels were normalized against those of GAPDH mRNA and expressed as a percentage of untreated cells. Statistical analysis was performed by Student's t test. P values are compared to the corresponding value for cells incubated in the absence of TNFa. *P < 0.05, **P < 0.01, ***P < 0.001. expression on human osteoblasts obtained from OA or osteoporotic patients was higher when compared to normal human osteoblasts. Also, IL-6 and PGE 2 levels in supernatant were found to be elevated with high ICAM-1 expression 34 . Several studies have demonstrated increased bone remodeling and osteoclast activity in OA 3 . Biphosphonates, drugs known to inhibit osteoclasts, and licofelone, a COX inhibitor capable of lowering IL-6 and PGE 2 levels, have been seen to reduce osteoclast activity in the setting of OA 3, 4 . Because of the role of ICAM-1 in osteoclast recruitment, its differential expression in diseases such as OA, and the increased osteoclast activity observed in OA, the understanding of the modulation of ICAM-1 expression and the mechanisms regulating it in OA bone could offer new potential therapeutic targets in OA.
So far, no study has looked at the expression and intracellular signaling of mICAM-1 and sICAM-1 in human osteoblasts. As demonstrated in our investigation, stimulation of osteoblasts with TNFa increased mICAM-1 and sICAM-1 expression at the protein and mRNA levels. It is noteworthy that sICAM-1 mRNA expression in response to TNFa occurs at a higher concentration (100-fold) than that of mI-CAM-1. However, it is possible to detect, in the extracellular milieu, a significant elevation of sICAM-1 after treatment 3 . TNFa-induced ICAM-1 required de novo mRNA synthesis. Human OA osteoblasts were pre-incubated for 1 h with 10 mg/ml ActD, followed by another incubation for 4 h with 10 ng/ml TNFa. One microgram of total RNA was processed for RT-PCR analysis to determine the mRNA levels of mICAM-1 (A), sICAM-1 (C), and GAPDH, as described in Materials and methods. Protein levels of mICAM-1 (B) and sICAM-1 (D) were determined by immunocytochemical staining and ELISA. The data are expressed as in the Fig. 1 legend (n ¼ 3) . Statistical analysis was performed by Student's t test. P values are compared to the corresponding value for cells incubated in the absence of TNFa. ***P < 0.001.
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with TNFa at a much lower concentration. This could simply reflect increased cleavage of already present mICAM-1 that is initiated at low TNFa concentration. However, if this were true, sICAM-1 levels would remain high with combined incubation of TNFa and ActD. Furthermore, in contrast to mI-CAM-1, sICAM-1 levels are not influenced by protein kinase inhibitors. Taken together, these results suggest that there are two separate pathways for the generation and regulation of mICAM-1 expression and sICAM-1 production in human OA osteoblasts. Our data seem to be in accordance with those of Wakatsuki et al. 23 who reported a specific mRNA coding for sI-CAM-1. We observed the presence of sICAM-1 mRNA splice in human osteoblasts using the specific primers of Wakatsuki et al. 23 . The meaning of this finding in bone remains to be defined. However, in various inflammatory and malignant pathological conditions, increased expression of sICAM-1 indicates a possible reciprocal relationship between sICAM-1 and inflammation 18, 19 . However, the relationship between circulating and membrane-bound ICAM-1 is controversial. Some studies report a similar physiological role for these two molecules, whereas others describe opposite actions 22,37e41 . We can only postulate whether sI-CAM-1 inhibits cellular adhesion or promotes the effect of mICAM-1 in bone metabolism. An anti-osteoclastogenic role for sICAM-1 would place it in the same category as osteoprotegerin (OPG), while a pro-osteoclastogenic role would potentially act in the same manner as soluble receptor activator of nuclear factor-kappaB ligand (sRANKL). Although the exact role of sICAM-1 remains elusive, we believe that increased mICAM-1 expression in response to TNFa stimulation could facilitate the interaction of osteoblasts with osteoclast precursors.
TNFa, a pleiotropic cytokine primarily produced by activated macrophages and T-lymphocytes, has a wide range of biological effects, including inflammation, mitogenesis, differentiation, immune modulation and anti-tumor immunity 42 . TNFa is also considered to be one of most important cytokines implicated in osteoporosis, arthritis and wear debris-induced osteolysis 28 . It supports the differentiation and survival of osteoclasts, but not resorption activity. The ability of osteoblasts to express adhesion molecules, such as ICAM-1, in addition to their ability to produce and respond to different cytokines, such as TNFa, IL-1b, IFN-g, transforming growth factor-beta (TGFb), and IL-6, suggests that osteoblasts can function as modulators and/or effectors of inflammatory processes and osteoclastogenesis. We believe that the osteoclastogenic action of these cytokines is, at least in part, modulated through ICAM-1.
Our results disclosed that the induction of ICAM-1 expression could be prevented by co-incubation with ActD (an inhibitor of RNA transcription). This means that the induction of ICAM-1 expression requires de novo mRNA synthesis, indicating its regulation at the transcriptional level. Investigations into the signal transduction pathways of TNFa showed rapid and significant phosphorylation of p38, p44/42, p54/46 MAPK as well as IkBa. Next, we tested the effects of MAPK-and NF-kB-specific inhibitors on TNFa-induced mICAM-1. Our data revealed that all chemical inhibitors, SB202190, PD98059 and PDTC, abrogated TNFa-induced mICAM-1 protein expression. Interestingly, these chemical products failed to inhibit sICAM-1 upregulation by TNFa. Furthermore, the overexpression of WT p38 MAPK and IKKa enhanced TNFa-induced mICAM-1. These results were supported by other recent studies indicating that TNFa is a potent inducer of ICAM-1 in various cell types 43, 44 . It has been reported that the activation of p38 MAPK and NF-kB appears necessary for the regulation of ICAM-1 expression. In the ICAM-1 promoter, numerous cis-elements have been identified to exert transcriptional control of ICAM-1. Among these elements, NF-kB and activator protein 1 (AP-1) were shown to act as the most critical of these regulatory elements for ICAM-1 transcription 45 . Mutation in the AP-1 and NF-kB sequence attenuates pro-inflammatory cytokine-stimulated ICAM-1 promoter activity 46, 47 . While increased sICAM-1 levels can be attributed to its transcriptional regulation, another mechanism has been considered crucial in sICAM-1. This mechanism includes the proteolytic cleavage of mICAM-1 by MMPs. To investigate it, osteoblasts were co-treated with 10 nM of an inhibitor of MMP-9 and 10 ng/ml TNFa. We observed that the addition of MMP-9 inhibitor I significantly reduced TNFa-enhanced sICAM-1 expression, which was consistent with other reports 20, 48 . Other inhibitors of MMP-9, such as Batimastat, have been shown to inhibit TNFainduced mICAM-1 cleavage in primary glial cells. Further experiments using a specific antibody for splice variantderived sICAM-1 (relative to conventional cell surface ICAM-1) will be performed to investigate the relationship between ICAM-1 and MMP-9.
Conclusion
This study reports an increase in ICAM-1 expression after the exposure of human osteoblasts to TNFa . This heightened expression appears to be mediated through activation of MAPK and IKKa cascades. Further, the regulation of sI-CAM-1 includes two mechanisms: (1) shedding/cleavage of conventional cell surface ICAM-1 protein by MMP-9, and (2) de novo synthesis from a specific coding mRNA. It is wellknown that ICAM-1 has a close relationship with inflammation, and TNFa has many effects in producing inflammatory responses. Therapeutic approaches have been taken to induce anti-inflammatory effects by blocking the ICAM-1 or TNFa-dependent pathway with a neutralizing antibody 49 . In bone disease, blockage of the interaction between TNFa and ICAM-1 may inhibit not only inflammation in the joint but also bone resorption by suppressing the inhibitor (10 nM), followed by incubation with or without TNFa (10 ng/ml) for another 24 h. Then, sICAM-1 expression was evaluated by ELISA. (B) Osteoblasts were treated with increasing concentrations of TNFa (0.1e10 ng/ml) for 24 h, and the culture medium was collected for Western blotting, using rabbit anti-MMP-9 antibody. Values are the means AE S.E.M. of three experiments. Statistical analysis was performed by Student's t test. P values represent control vs MMP-9 inhibitor, control vs TNFa, control vs TNFa þ MMP-9 inhibitor, and TNFa vs TNFa þ MMP-9 inhibitor. *P < 0.05, **P < 0.01.
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osteoblast-mediated formation of osteoclasts 49 . These findings could have clinical implications in the future treatment of bone loss diseases, such as osteoporosis, arthritis and aseptic loosening.
